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INTRODUCTION 
Dorzolamide 
1
 (DRZ) chemically [(4S, 6S) ‐4‐ 
(Ethylamino) ‐6‐methyl‐ 5, 6‐ dihydro‐4H thieno [2,3b] 
thiopyran‐ 2‐sulphonamide 7, 7‐dioxide hydrochloride] has 
a molecular fo rmula C10H16N2O4S3 and molecular weight 
324.44. Dorzolamide (Figure 1) is a carbonic anhydrase 
inhibitor. It is a sulfonamide and a highly specific carbonic 
anhydrase II inhibitor, which is the main carbonic 
anhydrase iso-enzyme involved in aqueous humor 
secretion. Inhibition of carbonic anhydrase -II in the ciliary  
processes of the eye decreases aqueous humor secretion, 
presumably by slowing the formation of bicarbonate ions 
with subsequent reduction in sodium and fluid transport. It 
is indicated for the reduction of elevated intra -ocular 
pressure in patients with open-angle glaucoma or ocular 
hypertension who are insufficiently responsive to beta-
blockers. Timolol maleate (TML)  (Figure 2) chemically  
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-y l-1,2,5-
thiadiazo l-3-y l)oxy]propan-2-ol is a non-selective beta-
adrenergic receptor blocker 
2
 and has a molecular formula 
C13H24N4O3S
  
with molecular weight 316.421 g/mol. It is 
used to treat open-angle and occasionally secondary 
glaucoma by reducing aqueous  humour production through 
blockage of the beta receptors on the ciliary epithelium. 
The pharmacological mechanism by which it actually does 
this is still unknown. Brimonidine (BMD) (Figure 3) was 
used as internal standard (IS). 
 
Figure 1:  Chemical Structure of Dorzolamide (DRZ) 
 
Figure 2:  Chemical Structure of Timolol maleate (TML) 
ABSTRACT 
A fast, sensitive and accurate reverse phase liquid chromatographic method was developed and 
validated for the simultaneous determination of Dorzolamide and Timolo l maleate in ophthalmic 
preparations. Chromatographic separation was achieved on Inertsil ODS 3V C18 co lumn (250 X 4.6 
mm, 5 µm particle size) with mobile phase consisting of Acetonitrile and 1-Octane Sulphonic acid 
buffer (0.02M) pH adjusted to 3.5 ± 0.05 with o-phosphoric acid (36:64 V/V) at a flow rate of 1.0 
mL/min. The analytes were detected at 254 nm and 295 nm for Dorzo lamide and Timolol maleate 
respectively by PDA detector. Brimonid ine was used as internal standard (IS). The retention time of 
Dorzolamide, Timolol maleate and Brimonidine were found to be at 6.020 ± 0.02, 8.254 ± 0.01 and 
4.636 ± 0.01 mins respectively. The linearity of the method ranged between 4-720 and 1-180 µg/mL 
for Dorzolamide and Timolol maleate respectively with correlat ion coefficient 0.999 for both the 
drugs in binary mixture. The LOD was found to be 0.6951 µg/mL and 0.2489 µg/mL for Dorzolamide 
and Timolol maleate respectively and LOQ was found to be 2.3214 µg/mL and 0.8317 µg/mL for 
Dorzolamide and Timolo l maleate respectively.  
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Figure 3:  Chemical Structure of Brimonidine (BMD) 
Both Dorzolamide and Timolol maleate have been 
analysed by various techniques either alone or in  
combination with other drugs. Several methods have been 
applied to determine Dorzolamide involving 
spectrophotometry 
3
, LC/MS 
4
, HPLC 
5
, Cap illary  
electrophoresis 
6
 and voltametry 
7
 where as Timolol 
maleate was determined by voltametry 
8
, HPTLC 
9
 and 
HPLC 
10
.    
Dorzolamide and Timolol maleate have been 
simultaneously analysed by spectrophotometry 
11
 and TLC 
/ ratio derivative spectrophotometry 
12
. Nevin Erk 
13
 et al 
and Nagori 
14
 developed HPLC methods with narrow 
linearity range for both the drugs. In this paper we reported 
a sensitive liquid chromatographic method with wide 
linearity range, good resolution where running time is less 
than 10 mins. The method has been validated as per the 
ICH guidelines 
15-16 
and can be successfully applied to 
pharmaceutical formulations. 
MATERIALS AND METHODS 
Reagents and Materials  
Reference standards of Dorzolamide, Timolol maleate and 
Brimonid ine were supplied by Micro Vision (India) with 
purity of 99.94%, 99.88 and 99.91% respectively. HPLC 
grade Acetonitrile (Merck), 1-Octane Sulphonic acid  
(Spectrochem), o-phosphoric acid and Milli Q water were 
used throughout the analysis. All other reagents were of 
analytical grade and were used without further 
purification. Mobile phase was filtered using 0.45µ 
membrane filters by Millipore (USA).   
Instrumentation  
The HPLC system is a binary gradient HPLC with Waters 
Alliance (Waters Corporation, MA, USA) equipped with a 
Waters 2695 separations module and a Waters 2695 PDA 
detector. Data acquisition was performed by the Empower 
pro-software operated on a Pentium® IV microprocessor. 
The experimental conditions were optimized with an 
Inertsil ODS 3V column (250 x 4.0 mm, 5 µm particle 
size) at room temperature.  
Chromatographic conditions   
The mobile phase consist of a mixture of (0.02M) 1-
Octane Sulphonic acid  buffer (pH 3.5) and Acetonitrile  
(64:36 V/V) respectively. The 1-Octane Sulphonic acid 
buffer was prepared by dissolving 4.35 grams of 1-Octane 
Sulphonic acid in a 1000ml o f volumetric flask with pH 
adjustment to 3.5 ± 0.05 with o-phosphoric acid. Flow rate  
of the mobile phase was 1.0 mL/ min .  
 
Preparation of stock solution 
Standard stock solution was prepared by dissolving 
accurately 200 mg Dorzo lamide and 50 mg Timolol 
maleate in 100 ml mobile phase. 5 ml of standard stock 
solution was diluted to 25 ml with mobile phase to obtain 
400 µg/mL Dorzolamide and 100 µg/mL Timolol maleate. 
The solution was filtered through 0.45µ nylon filter before 
analysis. 10 mg of Brimonidine was accurately weighed 
and dissolved in a 100 ml volumetric flask (100 µg/mL) 
with mobile phase. A series of solutions containing 
Dorzolamide and Timolol maleate (4:1) were prepared 
along with Brimonid ine (20 µg/mL) as internal standard 
were prepared with mobile phase and 10 µl of these 
solutions were in jected in to the HPLC system.  
Preparation of sample solution 
Commercial eye d rops MISOPT ( 2%, 5 ml) and 
OCUDOR ( 2%, 5 ml) were purchased from the local 
market and 2 ml of sample solution was diluted to obtain 
Dorzolamide and Timolol maleate as 400 and 100 µg/ml
 
with mobile phase. The solution was filtered through 0.45µ 
nylon filter before analysis. A series of d iluted solutions 
containing the mixture of Dorzolamide and Timolol 
maleate of the extracted formulat ion were prepared along 
with the internal standard (20 µg/mL) were prepared with 
mobile phase and 10 µl of these solutions were injected in  
to the HPLC system. 
Method Validation 
Linearity   
Linearity of the method was evaluated at different 
concentration levels by diluting the standard Dorzolamide 
and Timolol maleate (4:1) solutions with IS (20 µg/mL) to 
give solutions over the range 4-720 µg/mL and 1-
180µg/mL
 
respectively. These were in jected in trip licate 
and the peak area ratio value of Dorzolamide to that of IS 
as well as Timolo l maleate to that of IS against their 
respective concentration were inputted into a Microsoft 
Excel® spreadsheet program to plot calibration curves .  
Limit of detection and limit of quantitation  
To calculate Limits of Detection (LOD) and Limits of 
Quantificat ion (LOQ) values, sequential dilutions prepared 
and analyzed by the proposed method. The LOD and LOQ 
established by evaluating the level (signal to noise ratio of 
3:1 and 10:1 respectively) at which the analytes can be 
readily detected and quantified with accuracy.  
Precision 
Precision was evaluated in terms of intra-day repeatability 
and inter-day reproducibility. The intra-day repeatability 
was investigated using three separate sample solutions 
each at three different levels (200, 400 and 600 µg/mL) 
prepared as reported above, from the freshly reconstructed 
eye drops formulations. Each solution was in jected in  
triplicate (n=3) and the peak area followed by peak ratio  
was calculated. The inter-day reproducibility was checked 
on three different days by analyzing the sample solutions 
at three different levels (n=3) and the % RSD values were 
calculated. 
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Accuracy  
To demonstrate the accuracy of the proposed method was 
ascertained by carrying out recovery studies employed by 
standard addition method. Known quantities of 
Dorzolamide and Timolol maleate along with the internal 
standard (20 µg/mL) were supplemented to pre-quantified 
sample solution and then experimental and true values 
compared i.e. freshly prepared placebo of the combined 
pharmaceutical formulation (Eye drops) were spiked with 
various amounts of pure Dorzolamide and Timolol maleate  
at 50, 100 and 150%. Each solution was injected in  
triplicate and the peak area ratio of Dorzolamide to that of 
IS as well as Timolol maleate to that of IS were calculated.  
RES ULTS AND DISCUSS ION   
Reverse phase liquid chromatography using silica-base 
column is successfully applied in many separations of 
pharmaceuticals. Asymmetric peaks, irreproducible 
retention and non-robust separation methods can be 
obtained.  In this work we proposed a simple, sensitive and 
accurate HPLC method for simultaneous determination of 
Dorzolamide and Timolo l maleate. To obtain symmetrical 
peaks with better resolution the chromatographic 
conditions i.e. eluent optimization (pH, silanol b lockers) 
were optimised. Various chromatographic conditions such 
as mobile phase composition, analytical columns with 
different packing materials (C8, C18, phenyl, cyano), and 
configurations (10, 15, 25cm columns) tested to obtain 
sharp peaks with reduced tailing and better resolution. 
Finally a Inertsil ODS 3V C18 column (250 X 4.6mm 5 
µm part icle size) co lumn selected which provided reduced 
peak tailing. Mobile phase selected from peak parameters 
(symmetry, tailing etc.), run time, ease of preparation and 
cost. The most suitable mobile phase composition found to 
be (0.02M) 1, Octane Sulphonic acid buffer (pH 3.5) and 
Acetonitrile in the ratio of (64:36 V/V). Typical 
chromatograms of Dorzo lamide (254 nm), Timolol 
maleate (295 nm) and Brimonidine (254 nm) alone under 
the above mentioned conditions were shown in Figure 4, 5 
and 6. 
 
 
 
Figure 4:  Typical chromatogram of Dorzo lamide (100 µg/mL) at 254 nm 
 
 
 
Figure 5:  Typical chromatogram of Timolol maleate (50 µg/mL) at 295 nm  
(Maleic acid eluted at 2.152 mins) 
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Figure 6:  Typical chromatogram of Brimonidine (20 µg/mL) at 254 nm 
Method Validation 
Linearity 
The proposed chromatographic method validated using 
ICH guidelines. Validation parameters performed include 
linearity, accuracy, precision, limit of detection and 
quantitation. Linear calibrat ion plots for the proposed 
method were obtained in the concentration range of 4-720 
µg/mL for Dorzolamide and 1 to 180 µg/mL for Timolol 
maleate in presence of Brimonidine as internal standard 
(Table1).  
The linear regression equation for Dorzolamide was found 
to be Y = 0.035X + 0.044 with correlat ion coefficient 
0.999 and the linear regression equation for Timolol 
maleate found to be Y = 0.016X - 0.002 with correlat ion 
coefficient 0.999.   
Table 1: Linearity for the simultaneous analysis of Dorzo lamide and Timolol maleate in presence of Brimonidine (n=3) 
Conc. 
DRZ (µg/mL) 
Peak area  ratio 
DRZ /  BMD 
Conc. 
TML (µg/mL) 
Peak area  ratio 
TML / BMD 
4 0.1533 1 0.0164 
8 0.287 2 0.032 
20 0.7505 5 0.0859 
40 1.4576 10 0.1656 
80 2.9295 20 0.3318 
160 5.8163 40 0.6641 
200 7.2106 50 0.8259 
240 8.715 60 1.0005 
320 11.592 80 1.3339 
400 14.3428 100 1.6548 
480 17.0474 120 1.9698 
560 19.8324 140 2.3006 
600 21.5454 150 2.5033 
720 25.8419 180 3.025 
 
 
Figure 7:  Representative chromatogram of Dorzolamide (200 µg/mL) with Brimonid ine (IS) (20 µg/mL) at 254 nm 
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Figure 8: Representative chromatogram of Timolol maleate (50 µg/mL) with Brimonidine (IS) (20 µg/mL) at 295 nm 
The representative chromatograms of Dorzolamide and 
Timolol maleate together in presence of IS at UV detection 
254 and 295 nm (PDA detector) were shown in Figure 7 
and Figure 8 respectively. 
Limit of Detection and Limit of Quantification 
LOD found to be 0.6951µg/mL and 0.2489 µg/mL for 
Dorzolamide and Timolo l maleate respectively (signal to 
noise ratio of 3:1). LOQ found to be 2.3214 µg/mL and 
0.8317 µg/mL for Dorzolamide and Timolol maleate 
respectively (signal to noise ratio of 10:1).   
Precision  
Within-day precision determined by injecting five standard 
solutions of three different concentrations on the same day 
(n=5) and between-day precision determined by inject ing 
the same solutions for consecutive days. Relative standard 
deviation (RSD %) of the peak area calculated to represent 
precision. The results of within-day and between-day 
precision presented in Table 2.  
Table 2: Intra-Day and Inter-Day Precision for the simultaneous analysis of Dorzolamide and Timolol maleate in presence 
of Brimonidine (n=3) 
Drug  Conc. 
(µg/mL) 
Intra-day Precision Inter-day precision 
Mean peak area ratio  
± SD 
RSD 
(% ) 
Mean peak area ratio  
± SD 
RSD (% ) 
 
DRZ 
200 7.2193 ± 0.0317   0.439 7.91227 ± 0.0497 0.628 
400 14.3793 ± 0.0549 0.382 15.9748 ± 0.0809 0.507 
600 21.4301 ± 0.1787 0.834 21.5478 ± 0.2413 1.12 
 
TML 
50 0.8269 ± 0.00373 0.449 0.9256 ± 0.00631 0.682 
100 1.6594 ± 0.00581 0.349 1.9934 ± 0.00993 0.498 
150 2.4896 ± 0.02163 0.868 2.5034 ± 0.0313 1.25 
SD = Standard deviation; RSD = Relative standard deviation 
Accuracy 
Accuracy of the method was performed by the standard 
addition technique. Three levels of solutions (50, 100 and 
150%) of the nominal analytical concentrations prepared. 
The recovery and relative standard deviation for each 
analyte has given in Table 3. Recovery studies showed the 
method to be highly accurate and suitable for intended use.  
Table 3: Accuracy for the simultaneous analysis of Dorzolamide and Timolol maleate in presence of Brimonid ine (n=3)  
 
Drug  
 
Sample 
level% 
Conc. (µg/ml) Amount 
recovered  
(µg/ml) 
%  Recovery %  
RSD  
Pure 
 
Formulation 
 
Total 
 
DRZ 
50 20 40 60 59.91 99.85 0.23 
100 40 40 80 79.45 99.31 0.36 
150 60 40 100 99.76 99.76 0.39 
 
TML 
50 5 10 15 14.84 98.93 0.83 
100 10 10 20 19.83 99.15 0.76 
150 15 10 25 24.75 98.99 0.69 
RSD = Relative standard deviation 
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Assay of the Tablet Dosage Forms  
Application of the proposed method checked by analyzing 
the Dorzo lamide and Timolol maleate in commercially  
available pharmaceutical formulat ions (MISOPT and 
OCUDOR eye drops). The results provided in Table 4 
showed high percentage recoveries and low RSD (%) 
values for both analytes.  
Table 4: Assay results of Dorzolamide and Timolo l maleate in commercial eye drops (Total volume = 5 ml)  
Brand Names 
 
Ingredient Label claim 
(% ) 
Drug Found 
(% ) 
%  Recovery 
MISOPT 
 
Dorzolamide  2.0 1.9965 99.83 
Timolol maleate  0.5 0.4947 98.94 
OCUDOR-T 
 
Dorzolamide 2.0 1.9985 99.93 
Timolol maleate  0.5 0.4949 98.98 
The representative chromatograms of Dorzolamide and 
Timolol maleate in presence of IS at UV detection 254 and 
295 nm (PDA detector) were shown in Figure 9, 10, 11 
and 12 respectively. The % recovery was found to be 
99.83-99.93 for Dorzolamide and 98.94-98.98 for Timolol 
maleate respectively. 
 
Figure 9: Typical chromatogram of DRZ (200 µg/mL) with BMD (20 µg/mL) with UV detection at 254 nm (MISOPT ® 
Eye Drops) 
 
Figure 10: Typical chromatogram of TML (50 µg/mL) with BMD (20 µg/mL) with UV detection at 295 nm (MISOPT ® 
Eye Drops) 
 
Figure 11: Typical chromatogram of DRZ (200 µg/mL) with BMD (20 µg/mL) with UV detection at 254 nm (OCUDOR ® 
Eye Drops) 
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Figure 12: Typical chromatogram of TML (50 µg/mL) with BMD (20 µg/mL) with UV detection at 295 nm (OCUDOR ® 
Eye Drops) 
System suitability  
As system suitability test is an integral part of 
chromatographic methods development and it is used to 
verify  that the system is adequate for the analysis to be 
performed, the parameter fo r Dorzolamide and Timolol 
maleate were evaluated. The theoretical p lates were found 
to be 8676 for DRZ and 10707 for TML (N >2000) 
respectively. The resolution was >1.5. The tailing factor 
was found to be 1.05 and 1.03 for DRZ and TML 
respectively.  
CONCLUS IONS  
The advantages of the proposed method involve a simple 
procedure for sample preparat ion and relatively short time 
of analysis. Apart from th is, it can be used for assays of 
Dorzolamide and Timolol maleate in biological flu ids or in 
pharmacokinetic investigations. The proposed method was 
validated by testing its linearity, accuracy, precision, limits 
of detection and quantitation. The results of the analysis of 
pharmaceutical dosage forms by the proposed methods are 
highly reproducible, reliab le, and are in good agreement 
with the label claims of the drug. The additives usually 
present in the pharmaceutical formulations of the assayed 
samples did not interfere with Dorzolamide and Timolol 
maleate. It may be said that the proposed methods are 
precise, sensitive, and accurate, so that these can be used 
as standard pharmacopoeial methods for the simultaneous 
determination of Dorzolamide and Timolo l maleate using 
the HPLC systems with PDA detector. 
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